Those who are current investors in Sucampo Pharmaceuticals, Inc. During the same period in the prior year, the firm earned $0.30 EPS. research analysts anticipate that Sucampo Pharmaceuticals, Inc. will post 1.12 EPS for the current fiscal year. They issued a "buy" rating and a $43.00 price target on the stock.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. According to these analysts, the Low Revenue Estimate for Sucampo Pharmaceuticals, Inc.is 73 Million and the High Revenue Estimate is 77.7 Million.
While looking at the Stock's Performance, Sucampo Pharmaceuticals, Inc. now shows a Weekly Performance of 3.62%, where Monthly Performance is 16.25%, Quarterly performance is 79.71%, 6 Months performance is 71.43% and yearly performance percentage is 39.33%.
Several other research analysts have also recently weighed in on SCMP. Maxim Group cut Sucampo Pharmaceuticals to a hold rating in a research note on Monday, January 1st.
Sucampo Pharmaceuticals, Inc. (SCMP) analysts on average have given a price target of $25.15 on SCMP stock. ValuEngine raised Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Sunday, December 31st. They issued a "buy" rating and a $14.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. The stock's average target of $17.50 is -4.89% below today's ($18.4) share price.
Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) traded down $0.35 during midday trading on Friday, hitting $18.05. SCMP has a beta of 1.46 and therefore an above average level of market volatility. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.75. It improved, as 4 investors sold CRAI shares while 35 reduced holdings. Sucampo Pharmaceuticals, Inc. The stock has a 50 day moving average of $12.62 and a 200 day moving average of $12.85. In addition, given that certain Sucampo stockholders holding approximately 32% of the outstanding Sucampo shares have entered into a tender and support agreement for this transaction, the investigation concerns whether the Sucampo Pharmaceuticals, Inc. Finally, Aperio Group LLC bought a new stake in Sucampo Pharmaceuticals in the third quarter valued at about $137,000. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company's stock worth $13,826,000 after acquiring an additional 103,808 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter.
Growth isn't very attractive to investors if companies are sacrificing profitability and shareholder returns to achieve that growth.
In other news, CFO Andrew P. Smith sold 1,766 shares of the business's stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Hot Stocks Point (HSP) makes sure to keep the information up to date and correct, but we didn't suggest or recommend buying or selling of any financial instrument unless that information is subsequently confirmed on your own.
WARNING: "Sucampo Pharmaceuticals (NASDAQ:SCMP) Downgraded by UBS Group to "Neutral" was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of USA & worldwide copyright & trademark legislation.
Analysts await Sucampo Pharmaceuticals, Inc.
A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.